LIA
BIO icon

Lynx Investment Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Lynx Investment Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$546 – 205
2024
Q2 		$546 Buy
+2
New +$582 ﹤0.01% 733

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lynx Investment Advisory's BIO Position: Q3 2024 in Review

Lynx Investment Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 2 shares — an estimated $546 sold.

Lynx Investment Advisory first reported a position in BIO in Q2 2024 and held it in 1 quarter. The position peaked at $546 in Q2 2024. 437 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Lynx Investment Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Lynx Investment Advisory sold 2 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $546.
  • Lynx Investment Advisory first reported a position in Bio-Rad Laboratories Class A in Q2 2024 and held it in 1 quarter.
  • Lynx Investment Advisory's Bio-Rad Laboratories Class A position peaked at $546 in Q2 2024.
  • 437 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.